Improved Renal Function in Initial Treatment Improves Patient Survival, Renal Outcomes, and Glucocorticoid-Related Complications in IgG4-Related Kidney Disease in Japan

Introduction: We aimed to clarify long-term renal prognosis, complications of malignancy, glucocorticoid (GC) toxicity, and mortality in immunoglobulin G4 (IgG4)-related kidney disease (IgG4-RKD). Methods: Reviewing the medical records of 95 patients with IgG4-RKD, we investigated clinical and patho...

Full description

Saved in:
Bibliographic Details
Main Authors: Ichiro Mizushima, Takako Saeki, Daisuke Kobayashi, Naoki Sawa, Hiroki Hayashi, Yoshinori Taniguchi, Hirosuke Nakata, Kazunori Yamada, Shoko Matsui, Tetsuhiko Yasuno, Kosuke Masutani, Tasuku Nagasawa, Hiroki Takahashi, Yoshifumi Ubara, Motoko Yanagita, Mitsuhiro Kawano
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Kidney International Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024923015565
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850222877638393856
author Ichiro Mizushima
Takako Saeki
Daisuke Kobayashi
Naoki Sawa
Hiroki Hayashi
Yoshinori Taniguchi
Hirosuke Nakata
Kazunori Yamada
Shoko Matsui
Tetsuhiko Yasuno
Kosuke Masutani
Tasuku Nagasawa
Hiroki Takahashi
Yoshifumi Ubara
Motoko Yanagita
Mitsuhiro Kawano
author_facet Ichiro Mizushima
Takako Saeki
Daisuke Kobayashi
Naoki Sawa
Hiroki Hayashi
Yoshinori Taniguchi
Hirosuke Nakata
Kazunori Yamada
Shoko Matsui
Tetsuhiko Yasuno
Kosuke Masutani
Tasuku Nagasawa
Hiroki Takahashi
Yoshifumi Ubara
Motoko Yanagita
Mitsuhiro Kawano
author_sort Ichiro Mizushima
collection DOAJ
description Introduction: We aimed to clarify long-term renal prognosis, complications of malignancy, glucocorticoid (GC) toxicity, and mortality in immunoglobulin G4 (IgG4)-related kidney disease (IgG4-RKD). Methods: Reviewing the medical records of 95 patients with IgG4-RKD, we investigated clinical and pathologic features at baseline, the course of renal function, complications of malignancy, GC toxicity, and mortality during follow-up (median 71 months). The standardized incidence ratio (SIR) of malignancy and standardized mortality ratio were calculated using national statistics. Factors related to outcomes were assessed by Cox regression analyses. Results: At diagnosis, the median estimated glomerular infiltration rate (eGFR) was 46 ml/min per 1.73 m2. GC achieved initial improvement. Additional renal function recovery within 3-months of initial treatment occurred in patients with highly elevated serum IgG and IgG4 levels and hypocomplementemia. During follow-up, 68%, 17%, and 3% of the patients had chronic kidney disease (CKD), >30% eGFR decline, and end-stage renal disease (ESRD), respectively. Age-adjusted and sex-adjusted Cox regression analyses indicated that eGFR (hazard ratio [HR], 0.71) and extensive fibrosis (HR, 2.58) at treatment initiation had a significant impact on the time to CKD. Ten patients died, and the standardized mortality ratio was 0.94. The SIR of malignancy was 1.52. The incidence rate (IR) of severe infection was 1.80/100 person-years. Cox regression analyses showed that the best eGFR within 3 months after treatment initiation were associated with lower mortality (HR 0.67) and fewer severe infections (HR 0.63). Conclusion: This study suggests that more renal function recovery through early treatment initiation may improve patient survival, renal outcomes, and some GC-related complications in IgG4-RKD.
format Article
id doaj-art-12ad52aeaae64a4e8cfb2ec3ad25cac1
institution OA Journals
issn 2468-0249
language English
publishDate 2024-01-01
publisher Elsevier
record_format Article
series Kidney International Reports
spelling doaj-art-12ad52aeaae64a4e8cfb2ec3ad25cac12025-08-20T02:06:11ZengElsevierKidney International Reports2468-02492024-01-0191526310.1016/j.ekir.2023.10.016Improved Renal Function in Initial Treatment Improves Patient Survival, Renal Outcomes, and Glucocorticoid-Related Complications in IgG4-Related Kidney Disease in JapanIchiro Mizushima0Takako Saeki1Daisuke Kobayashi2Naoki Sawa3Hiroki Hayashi4Yoshinori Taniguchi5Hirosuke Nakata6Kazunori Yamada7Shoko Matsui8Tetsuhiko Yasuno9Kosuke Masutani10Tasuku Nagasawa11Hiroki Takahashi12Yoshifumi Ubara13Motoko Yanagita14Mitsuhiro Kawano15Department of Rheumatology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan; Correspondence: Ichiro Mizushima, Department of Rheumatology, Kanazawa University Hospital, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8640, Japan.Department of Internal Medicine, Nagaoka Red Cross Hospital, Nagaoka, JapanDivision of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata City, JapanDepartment of Nephrology Center, Toranomon Hospital, Kawasaki, JapanDepartment of Nephrology, Fujita Health University School of Medicine, Toyoake, JapanDepartment of Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi University, Nankoku-shi, JapanDepartment of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto City, JapanDepartment of Hematology and Immunology, Kanazawa Medical University, Kahoku-gun, JapanHealth Administration Center, University of Toyama, Toyama City, JapanDivision of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fukuoka University, Jonan-Ku, JapanDivision of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fukuoka University, Jonan-Ku, JapanDivision of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Hospital, Sendai, JapanDepartment of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, JapanDepartment of Nephrology Center, Toranomon Hospital, Kawasaki, JapanDepartment of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto City, JapanDepartment of Rheumatology, Graduate School of Medical Science, Kanazawa University, Kanazawa, JapanIntroduction: We aimed to clarify long-term renal prognosis, complications of malignancy, glucocorticoid (GC) toxicity, and mortality in immunoglobulin G4 (IgG4)-related kidney disease (IgG4-RKD). Methods: Reviewing the medical records of 95 patients with IgG4-RKD, we investigated clinical and pathologic features at baseline, the course of renal function, complications of malignancy, GC toxicity, and mortality during follow-up (median 71 months). The standardized incidence ratio (SIR) of malignancy and standardized mortality ratio were calculated using national statistics. Factors related to outcomes were assessed by Cox regression analyses. Results: At diagnosis, the median estimated glomerular infiltration rate (eGFR) was 46 ml/min per 1.73 m2. GC achieved initial improvement. Additional renal function recovery within 3-months of initial treatment occurred in patients with highly elevated serum IgG and IgG4 levels and hypocomplementemia. During follow-up, 68%, 17%, and 3% of the patients had chronic kidney disease (CKD), >30% eGFR decline, and end-stage renal disease (ESRD), respectively. Age-adjusted and sex-adjusted Cox regression analyses indicated that eGFR (hazard ratio [HR], 0.71) and extensive fibrosis (HR, 2.58) at treatment initiation had a significant impact on the time to CKD. Ten patients died, and the standardized mortality ratio was 0.94. The SIR of malignancy was 1.52. The incidence rate (IR) of severe infection was 1.80/100 person-years. Cox regression analyses showed that the best eGFR within 3 months after treatment initiation were associated with lower mortality (HR 0.67) and fewer severe infections (HR 0.63). Conclusion: This study suggests that more renal function recovery through early treatment initiation may improve patient survival, renal outcomes, and some GC-related complications in IgG4-RKD.http://www.sciencedirect.com/science/article/pii/S2468024923015565deathglucocorticoidIgG4-related kidney diseasemalignancyoutcometreatment
spellingShingle Ichiro Mizushima
Takako Saeki
Daisuke Kobayashi
Naoki Sawa
Hiroki Hayashi
Yoshinori Taniguchi
Hirosuke Nakata
Kazunori Yamada
Shoko Matsui
Tetsuhiko Yasuno
Kosuke Masutani
Tasuku Nagasawa
Hiroki Takahashi
Yoshifumi Ubara
Motoko Yanagita
Mitsuhiro Kawano
Improved Renal Function in Initial Treatment Improves Patient Survival, Renal Outcomes, and Glucocorticoid-Related Complications in IgG4-Related Kidney Disease in Japan
Kidney International Reports
death
glucocorticoid
IgG4-related kidney disease
malignancy
outcome
treatment
title Improved Renal Function in Initial Treatment Improves Patient Survival, Renal Outcomes, and Glucocorticoid-Related Complications in IgG4-Related Kidney Disease in Japan
title_full Improved Renal Function in Initial Treatment Improves Patient Survival, Renal Outcomes, and Glucocorticoid-Related Complications in IgG4-Related Kidney Disease in Japan
title_fullStr Improved Renal Function in Initial Treatment Improves Patient Survival, Renal Outcomes, and Glucocorticoid-Related Complications in IgG4-Related Kidney Disease in Japan
title_full_unstemmed Improved Renal Function in Initial Treatment Improves Patient Survival, Renal Outcomes, and Glucocorticoid-Related Complications in IgG4-Related Kidney Disease in Japan
title_short Improved Renal Function in Initial Treatment Improves Patient Survival, Renal Outcomes, and Glucocorticoid-Related Complications in IgG4-Related Kidney Disease in Japan
title_sort improved renal function in initial treatment improves patient survival renal outcomes and glucocorticoid related complications in igg4 related kidney disease in japan
topic death
glucocorticoid
IgG4-related kidney disease
malignancy
outcome
treatment
url http://www.sciencedirect.com/science/article/pii/S2468024923015565
work_keys_str_mv AT ichiromizushima improvedrenalfunctionininitialtreatmentimprovespatientsurvivalrenaloutcomesandglucocorticoidrelatedcomplicationsinigg4relatedkidneydiseaseinjapan
AT takakosaeki improvedrenalfunctionininitialtreatmentimprovespatientsurvivalrenaloutcomesandglucocorticoidrelatedcomplicationsinigg4relatedkidneydiseaseinjapan
AT daisukekobayashi improvedrenalfunctionininitialtreatmentimprovespatientsurvivalrenaloutcomesandglucocorticoidrelatedcomplicationsinigg4relatedkidneydiseaseinjapan
AT naokisawa improvedrenalfunctionininitialtreatmentimprovespatientsurvivalrenaloutcomesandglucocorticoidrelatedcomplicationsinigg4relatedkidneydiseaseinjapan
AT hirokihayashi improvedrenalfunctionininitialtreatmentimprovespatientsurvivalrenaloutcomesandglucocorticoidrelatedcomplicationsinigg4relatedkidneydiseaseinjapan
AT yoshinoritaniguchi improvedrenalfunctionininitialtreatmentimprovespatientsurvivalrenaloutcomesandglucocorticoidrelatedcomplicationsinigg4relatedkidneydiseaseinjapan
AT hirosukenakata improvedrenalfunctionininitialtreatmentimprovespatientsurvivalrenaloutcomesandglucocorticoidrelatedcomplicationsinigg4relatedkidneydiseaseinjapan
AT kazunoriyamada improvedrenalfunctionininitialtreatmentimprovespatientsurvivalrenaloutcomesandglucocorticoidrelatedcomplicationsinigg4relatedkidneydiseaseinjapan
AT shokomatsui improvedrenalfunctionininitialtreatmentimprovespatientsurvivalrenaloutcomesandglucocorticoidrelatedcomplicationsinigg4relatedkidneydiseaseinjapan
AT tetsuhikoyasuno improvedrenalfunctionininitialtreatmentimprovespatientsurvivalrenaloutcomesandglucocorticoidrelatedcomplicationsinigg4relatedkidneydiseaseinjapan
AT kosukemasutani improvedrenalfunctionininitialtreatmentimprovespatientsurvivalrenaloutcomesandglucocorticoidrelatedcomplicationsinigg4relatedkidneydiseaseinjapan
AT tasukunagasawa improvedrenalfunctionininitialtreatmentimprovespatientsurvivalrenaloutcomesandglucocorticoidrelatedcomplicationsinigg4relatedkidneydiseaseinjapan
AT hirokitakahashi improvedrenalfunctionininitialtreatmentimprovespatientsurvivalrenaloutcomesandglucocorticoidrelatedcomplicationsinigg4relatedkidneydiseaseinjapan
AT yoshifumiubara improvedrenalfunctionininitialtreatmentimprovespatientsurvivalrenaloutcomesandglucocorticoidrelatedcomplicationsinigg4relatedkidneydiseaseinjapan
AT motokoyanagita improvedrenalfunctionininitialtreatmentimprovespatientsurvivalrenaloutcomesandglucocorticoidrelatedcomplicationsinigg4relatedkidneydiseaseinjapan
AT mitsuhirokawano improvedrenalfunctionininitialtreatmentimprovespatientsurvivalrenaloutcomesandglucocorticoidrelatedcomplicationsinigg4relatedkidneydiseaseinjapan